Your browser doesn't support javascript.
loading
Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
Kaczmarek, E; Saint-Martin, C; Pierga, J-Y; Brain, E; Rouzier, R; Savignoni, A; Mouret-Fourme, E; Dieras, V; Piot, I; Dubot, C; Carton, M; Lerebours, F.
Affiliation
  • Kaczmarek E; Department of Medical Oncology, Oscar Lambret Center, Lille, France. e-kaczmarek@o-lambret.fr.
  • Saint-Martin C; Department of Biostatistics, Institut Curie, Paris, France. e-kaczmarek@o-lambret.fr.
  • Pierga JY; Department of Medical Oncology, Institut Curie, Paris, France. e-kaczmarek@o-lambret.fr.
  • Brain E; Department of Surgical Oncology, Institut Curie, Paris, France. e-kaczmarek@o-lambret.fr.
  • Rouzier R; R&D, Unicancer, UCBG, Paris, France. e-kaczmarek@o-lambret.fr.
  • Savignoni A; Department of Medical Oncology, Oscar Lambret Center, Lille, France.
  • Mouret-Fourme E; Department of Biostatistics, Institut Curie, Paris, France.
  • Dieras V; Department of Medical Oncology, Institut Curie, Paris, France.
  • Piot I; Department of Surgical Oncology, Institut Curie, Paris, France.
  • Dubot C; R&D, Unicancer, UCBG, Paris, France.
  • Carton M; Department of Medical Oncology, Oscar Lambret Center, Lille, France.
  • Lerebours F; Department of Biostatistics, Institut Curie, Paris, France.
Breast Cancer Res Treat ; 178(3): 505-512, 2019 Dec.
Article in En | MEDLINE | ID: mdl-31486993
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Trastuzumab / Antineoplastic Agents, Immunological Type of study: Prognostic_studies Limits: Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2019 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Trastuzumab / Antineoplastic Agents, Immunological Type of study: Prognostic_studies Limits: Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2019 Document type: Article